Assembly Biosciences
ASMB
107 hedge funds and large institutions have $133M invested in Assembly Biosciences in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 16 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
12% more call options, than puts
Call options by funds: $550K | Put options by funds: $493K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.58% less ownership
Funds ownership: 6.84% → 6.26% (-0.58%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 109 → 107 (-2)
18% less capital invested
Capital invested by funds: $163M → $133M (-$30.2M)
Top Buyers
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.2M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$3.36M |
| 3 |
Two Sigma Advisers
New York
|
+$3.2M |
| 4 |
Two Sigma Investments
New York
|
+$3.06M |
| 5 |
BlackRock
New York
|
+$2.81M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$11.9M |
| 2 |
Morgan Stanley
New York
|
-$2.3M |
| 3 |
AC
Armistice Capital
New York
|
-$2.14M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.81M |
| 5 |
AI
Atom Investors
Austin,
Texas
|
-$1.47M |
ASMB Hedge Fund Activity: Q1 2021 in Review
107 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2021, worth a combined $133M — down 18% from $163M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ASMB and 15 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 38 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $6.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $11.9M sold.
- 107 institutional investors held Assembly Biosciences (ASMB) as of Q1 2021, down from 109 in Q4 2020.
- Funds reported $133M of Assembly Biosciences stock for Q1 2021, down 18% quarter-over-quarter.
- 15 funds opened new Assembly Biosciences positions in Q1 2021 and 16 closed out, a net change of -1 holder.
- The largest Assembly Biosciences buyer in Q1 2021 was Soleus Capital Management, an estimated $6.2M added.
- The largest Assembly Biosciences seller in Q1 2021 was Consonance Capital Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2021.